CYP1A2 Isoform Quantitation via LC-MS/MS Peptide Monitoring
Solution Overview
Problem
Current methods for evaluating cytochrome P450 enzyme induction, such as mRNA-based assays and protein expression techniques, are unreliable due to transcriptional and translational regulation, and poor discriminatory power within enzyme subfamilies, making it challenging to accurately quantify specific isoforms like CYP 1A2.
Innovation Solution
A method using tandem mass spectrometry (MS/MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) to detect and quantify specific tryptic peptides of CYP 1A2 without chemical labeling, employing Multiple Reaction Monitoring (MRM) with a triple quadrupole instrument and utilizing 'housekeeping' proteins for normalization, allowing for reliable isoform-specific quantitation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If mRNA-based assays are used to evaluate CYP induction, then the evaluation can be performed early in the development process, but the results are unreliable due to transcriptional and translational regulation
Solution Approach 1:
The patent extracts and measures actual CYP protein levels directly from hepatocyte samples using mass spectrometry, bypassing the unreliable mRNA-based prediction pathway. This extraction of the actual target molecule (CYP protein) rather than its upstream indicator (mRNA) resolves the contradiction by providing reliable early evaluation data.
Solution Approach 2:
The patent replaces the biological assay system (mRNA-based evaluation) with a mass spectrometry-based detection system. This substitution uses physical measurement principles (mass-to-charge ratio detection) instead of biological response measurement, thereby achieving both early evaluation capability and high reliability.
2Reliability
If protein expression methods are used to detect CYP isoforms, then direct protein measurement is achieved, but the methods are poorly discriminatory due to extensive amino acid sequence homology within subfamilies
Solution Approach 1:
The patent segments the CYP protein into smaller peptide fragments through enzymatic digestion. By measuring specific peptide sequences unique to each isoform rather than the entire protein, the method achieves isoform-specific discrimination despite overall sequence homology. This segmentation allows differentiation at the peptide level where sequence variations are more distinguishable.
Solution Approach 2:
The patent focuses measurement on specific local regions (unique peptide sequences) within the CYP protein structure rather than attempting to measure the entire protein uniformly. By targeting isoform-specific peptide regions, the method achieves high discriminatory power for individual isoforms while maintaining reliable protein expression measurement.
3Measurement precision
If chemical labeling methods are used for CYP quantitation, then detection sensitivity can be enhanced, but the process becomes more complex and requires additional reagents
Solution Approach 1:
The patent employs stable isotope-labeled internal standards that naturally co-elute with the target peptides during chromatography and are detected simultaneously by mass spectrometry. The labeled standards serve as built-in references that automatically correct for variations in sample preparation and instrument response, providing self-calibrating quantitation without additional complex procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and reliable quantitation of CYP 1A2 isoform in samples, improving the assessment of drug induction potential by providing a sensitive and specific method for CYP induction analysis, which aligns with protein expression changes observed in hepatocyte samples.
Implementation Method 1
the mass spectrometry technique comprises a tandem spectrometry (MS/MS) technique
Implementation Method 2
or a liquid chromatography tandem mass spectrometry (LC-MS/MS) technique
Implementation Method 3
the technique comprising using a triple quadrupole instrument and Multiple Reaction Monitoring (MRM)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method for screening a drug for cytochrome P450 (CYP) induction is provided and can include incubating the drug with a microsome-containing biological sample and then quantitating at least one cytochrome P450 isoform. The isoforms can be selected from 2B6, 3A4, 1A2, and 3A5 isoforms. In some embodiments, the method uses liquid chromatography tandem mass spectrometry (LC-MSMS). A quantitated value can be compared to a threshold value and the drug can be determined to exhibit an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. Isolated peptides are also provided.